These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38142214)

  • 1. An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.
    Langley JM; Gantt S; Halperin SA; Ward B; McNeil S; Ye L; Cai Y; Smith B; Anderson DE; Mitoma FD
    Vaccine; 2024 Jan; 42(3):713-722. PubMed ID: 38142214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
    Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
    Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.
    Schleiss MR; Choi KY; Anderson J; Mash JG; Wettendorff M; Mossman S; Van Damme M
    Vaccine; 2014 May; 32(23):2756-62. PubMed ID: 23867012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial.
    Fierro C; Brune D; Shaw M; Schwartz H; Knightly C; Lin J; Carfi A; Natenshon A; Kalidindi S; Reuter C; Miller J; Panther L
    J Infect Dis; 2024 Sep; 230(3):e668-e678. PubMed ID: 38478705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers.
    Mitchell DK; Holmes SJ; Burke RL; Duliege AM; Adler SP
    Pediatr Infect Dis J; 2002 Feb; 21(2):133-8. PubMed ID: 11840080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
    Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
    J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Das R; Blázquez-Gamero D; Bernstein DI; Gantt S; Bautista O; Beck K; Conlon A; Rosenbloom DIS; Wang D; Ritter M; Arnold B; Annunziato P; Russell KL;
    Lancet Infect Dis; 2023 Dec; 23(12):1383-1394. PubMed ID: 37660711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.
    Song JY; Choi WS; Heo JY; Lee JS; Jung DS; Kim SW; Park KH; Eom JS; Jeong SJ; Lee J; Kwon KT; Choi HJ; Sohn JW; Kim YK; Noh JY; Kim WJ; Roman F; Ceregido MA; Solmi F; Philippot A; Walls AC; Carter L; Veesler D; King NP; Kim H; Ryu JH; Lee SJ; Park YW; Park HK; Cheong HJ
    EClinicalMedicine; 2022 Sep; 51():101569. PubMed ID: 35879941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
    McVoy MA; Lee R; Saccoccio FM; Hartikka J; Smith LR; Mahajan R; Wang JB; Cui X; Adler SP
    Vaccine; 2015 Dec; 33(51):7328-7336. PubMed ID: 26597035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
    Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
    Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
    Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
    Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
    Adler SP; Lewis N; Conlon A; Christiansen MP; Al-Ibrahim M; Rupp R; Fu TM; Bautista O; Tang H; Wang D; Fisher A; Culp T; Das R; Beck K; Tamms G; Musey L;
    J Infect Dis; 2019 Jul; 220(3):411-419. PubMed ID: 31535143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.
    Schleiss MR; Bourne N; Stroup G; Bravo FJ; Jensen NJ; Bernstein DI
    J Infect Dis; 2004 Apr; 189(8):1374-81. PubMed ID: 15073673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model.
    Choi KY; El-Hamdi NS; McGregor A
    Vaccine; 2020 Feb; 38(10):2340-2349. PubMed ID: 32008881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
    Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
    Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
    August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
    Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
    Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of epitopes of human monoclonal antibodies against cytomegalovirus glycoprotein B for neutralization and antibody-dependent phagocytosis.
    Yamaguchi K; Shimizu H; Takahashi K; Nagatomo T; Nishimura T; Matsumoto M; Koshizuka T; Mori H; Inoue N; Torikai M
    Vaccine; 2023 Jul; 41(31):4497-4507. PubMed ID: 37321896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.